Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 09:02 am Purchase | 2024-12-31 | 13G | Allogene Therapeutics, Inc. ALLO | Lynx1 Capital Management LP | 10,874,723 5.200% | 10,874,723 (New Position) | Filing History |
| 2025-02-14 09:01 am Purchase | 2024-12-31 | 13G | Passage Bio, Inc. PASG | Lynx1 Capital Management LP | 9,256,953 15.000% | 829,998 (+9.85%) | Filing History |
| 2025-02-14 09:01 am Purchase | 2024-12-31 | 13G | Precision BioSciences, Inc. DTIL | Lynx1 Capital Management LP | 766,051 9.990% | 766,051 (New Position) | Filing History |
| 2025-02-14 09:00 am Purchase | 2024-12-31 | 13G | TScan Therapeutics, Inc. TCRX | Lynx1 Capital Management LP | 5,357,347 10.900% | 132,747 (+2.54%) | Filing History |
| 2025-02-10 5:29 pm Purchase | 2025-02-06 | 13G | GH Research PLC GHRS | Lynx1 Capital Management LP | 6,353,069 10.200% | 1,494,075 (+30.75%) | Filing History |
| 2025-02-10 5:22 pm Purchase | 2024-12-31 | 13G | GH Research PLC GHRS | Lynx1 Capital Management LP | 4,858,994 9.300% | 663,100 (+15.80%) | Filing History |
| 2024-11-14 09:07 am Sale | 2024-09-30 | 13G | Pieris Pharmaceuticals, Inc. PIRS | Lynx1 Capital Management LP | 37,436 2.800% | -84,762 (-69.36%) | Filing History |
| 2024-11-14 09:05 am Purchase | 2024-09-30 | 13G | GH Research PLC GHRS | Lynx1 Capital Management LP | 4,195,894 8.100% | 1,201,835 (+40.14%) | Filing History |
| 2024-11-14 09:03 am Sale | 2024-09-30 | 13G | Bionomics Limited BNOX | Lynx1 Capital Management LP | 8,245,095 3.200% | -4,119,480 (-33.32%) | Filing History |
| 2024-11-14 09:01 am Purchase | 2024-09-30 | 13G | C4 Therapeutics, Inc. CCCC | Lynx1 Capital Management LP | 6,880,527 9.900% | 3,746,131 (+119.52%) | Filing History |
| 2024-11-14 09:00 am Purchase | 2024-09-30 | 13G | Stoke Therapeutics, Inc. STOK | Lynx1 Capital Management LP | 5,187,191 9.900% | 2,230,273 (+75.43%) | Filing History |
| 2024-08-09 5:15 pm Purchase | 2024-08-07 | 13G | Passage Bio, Inc. PASG | Lynx1 Capital Management LP | 8,426,955 13.600% | 3,581,084 (+73.90%) | Filing History |
| 2024-04-01 7:23 pm Purchase | 2024-03-26 | 13G | iBio, Inc. IBIO | Lynx1 Capital Management LP | 878,492 9.990% | 878,492 (New Position) | Filing History |
| 2024-03-29 4:15 pm Purchase | 2024-03-19 | 13G | Passage Bio, Inc. PASG | Lynx1 Capital Management LP | 4,845,871 8.700% | 4,466,712 (+1178.06%) | Filing History |
| 2024-02-16 4:57 pm Purchase | 2024-02-06 | 13G | GH Research PLC GHRS | Lynx1 Capital Management LP | 2,994,059 5.800% | 2,994,059 (New Position) | Filing History |
| 2024-02-14 09:22 am Purchase | 2023-12-31 | 13G | Alpine Immune Sciences, Inc. ALPN | Lynx1 Capital Management LP | 3,813,926 6.600% | 687,753 (+22.00%) | Filing History |
| 2024-02-14 09:21 am Sale | 2023-12-31 | 13G | Kinnate Biopharma Inc. KNTE | Lynx1 Capital Management LP | 1,997,006 4.200% | -216,172 (-9.77%) | Filing History |
| 2024-02-14 09:21 am Sale | 2023-12-31 | 13G | Passage Bio, Inc. PASG | Lynx1 Capital Management LP | 379,159 0.700% | -2,976,758 (-88.70%) | Filing History |
| 2024-02-14 09:21 am Purchase | 2023-12-31 | 13G | C4 Therapeutics, Inc. CCCC | Lynx1 Capital Management LP | 3,134,396 6.400% | 12,177 (+0.39%) | Filing History |
| 2024-02-14 09:20 am Purchase | 2023-12-31 | 13G | Stoke Therapeutics, Inc. STOK | Lynx1 Capital Management LP | 2,956,918 6.600% | 292,760 (+10.99%) | Filing History |